SEMA4A and breast cancer: The addition of recombinant SEMA4A additionally induced the proliferation of T cells and improved the therapeutic efficacy of anti-PD-1 antibodies in vivo, suggesting that SEMA4A can be used as an important biomarker to assess the response to immune checkpoint inhibitors [61]—this has not yet been assessed in BC.